Barrett’s Esophagus
Videos
Overview
Barrett's esophagus is a change in the lining of the lower esophagus in which the normal squamous epithelium is replaced by columnar epithelium containing intestinal metaplasia, developing in response to chronic acid reflux injury (Russin et al., Alimentary Pharmacology & Therapeutics, 2026; Wani et al., AGA Guideline, 2025). A formal diagnosis requires at least 1 cm of columnar-lined esophagus above the gastroesophageal junction with intestinal metaplasia confirmed on biopsy (Shaheen et al., ACG Guideline, 2022). It affects roughly 1–2% of the general adult population, and about 5–7% of adults with chronic GERD (Thrift, Nature Reviews Gastroenterology & Hepatology, 2021; Maret-Ouda et al., JAMA, 2020).
Barrett's esophagus matters because it is the only known precursor to esophageal adenocarcinoma — a cancer whose incidence has risen roughly 5-fold since the 1970s and whose overall 5-year survival remains under 20% (Wani et al., AGA Guideline, 2025). Progression follows a stepwise sequence from non-dysplastic Barrett's to low-grade dysplasia, high-grade dysplasia, and finally cancer, with the annual risk rising sharply at each step: about 0.2–0.5% per year for non-dysplastic disease, ~0.5–0.7% per year for confirmed low-grade dysplasia, and 5–7% per year for high-grade dysplasia (Russin et al., Alimentary Pharmacology & Therapeutics, 2026; Thrift, Nature Reviews Gastroenterology & Hepatology, 2021). Importantly, most patients with non-dysplastic Barrett's never develop cancer, which is why risk stratification and surveillance — not alarm — drive management (Fitzgerald, New England Journal of Medicine, 2026).
Causes
The primary cause of Barrett’s esophagus is chronic gastroesophageal reflux disease (GERD). Persistent acid exposure damages the esophageal lining, triggering cellular changes. Additional contributors include hiatal hernia, obesity, smoking, and genetic predisposition.
Risk Factor
Risk factors include chronic GERD, age over 50, male sex, obesity (especially central obesity), smoking, family history of Barrett’s or esophageal cancer, and the presence of a hiatal hernia.
How Barrett's Esophagus Affects the Body
Barrett’s esophagus alters the normal esophageal lining, making it more vulnerable to inflammation, ulceration, and progression to dysplasia. Over time, these changes increase the risk of esophageal cancer, particularly adenocarcinoma.
Complications
Complications include esophagitis, strictures, dysplasia (low‑ or high‑grade), and esophageal adenocarcinoma. Patients with Barrett’s require regular surveillance to detect early changes.
Symptoms and Signs
Barrett’s esophagus itself often has no symptoms. Most patients experience symptoms of GERD, including heartburn, regurgitation, chest discomfort, chronic cough, hoarseness, or difficulty swallowing.
Diagnosis
Barrett's esophagus is diagnosed at upper endoscopy (EGD) when a salmon-colored columnar segment of at least 1 cm is seen above the gastroesophageal junction and biopsies confirm intestinal metaplasia; a structured (Seattle protocol) biopsy approach is used, and any dysplasia should be confirmed by a second GI pathologist (Shaheen et al., ACG Guideline, 2022). Population-wide screening is not recommended; instead, a single screening endoscopy is suggested for patients with chronic GERD plus additional risk factors such as male sex, age over 50, White race, smoking, obesity, and a family history of Barrett's or esophageal adenocarcinoma (Shaheen et al., ACG Guideline, 2022; Fitzgerald, New England Journal of Medicine, 2026). Swallowable non-endoscopic cell-collection devices paired with biomarkers are an emerging, acceptable alternative for screening (Shaheen et al., ACG Guideline, 2022).
Once Barrett's is found, the surveillance interval is driven by the grade of dysplasia and the length of the segment (Iyer & Chak, Gastroenterology, 2023):
- Non-dysplastic Barrett's — surveillance every 3–5 years, with current ACG guidance of every 5 years for short segments (<3 cm) and every 3 years for long segments (≥3 cm), reflecting the much lower progression risk of short segments (0.06% vs 0.31% per year) (Iyer & Chak, Gastroenterology, 2023; Sharma, JAMA, 2022).
- Indefinite for dysplasia — optimize acid suppression and repeat endoscopy in 3–6 months (Iyer & Chak, Gastroenterology, 2023).
- Confirmed low-grade dysplasia — endoscopic eradication therapy or close surveillance every 6–12 months, after expert pathology confirmation (Iyer & Chak, Gastroenterology, 2023).
- High-grade dysplasia / intramucosal cancer — referred for endoscopic eradication therapy (Iyer & Chak, Gastroenterology, 2023).
The length of the segment is formally recorded using the Prague C & M classification (circumferential extent "C" and maximal extent "M" in cm above the gastroesophageal junction), which standardizes reporting and guides surveillance (Shaheen et al., ACG Guideline, 2022).
.
Differential Diagnosis
Conditions that may mimic or coexist with Barrett’s include esophagitis, eosinophilic esophagitis, esophageal strictures, GERD without metaplasia, and esophageal cancer.
Lifestyle Modifications
Lifestyle changes include weight loss, avoiding trigger foods, reducing caffeine and alcohol, quitting smoking, elevating the head of the bed, and avoiding late meals.
Treatment Options
Treatment has two distinct goals — controlling reflux and, when dysplasia is present, eradicating the Barrett's tissue itself (Fitzgerald, New England Journal of Medicine, 2026):
- Acid control for non-dysplastic Barrett's. Proton pump inhibitors are recommended for symptom control and to reduce inflammation-related complications; acid suppression does not make Barrett's regress, and endoscopic therapy is not recommended for non-dysplastic disease (Fitzgerald, New England Journal of Medicine, 2026; Maret-Ouda et al., JAMA, 2020). For patients with proven reflux who have inadequate symptom control or intolerable medication side effects, antireflux surgery is a good alternative (Fitzgerald, New England Journal of Medicine, 2026).
- Endoscopic eradication therapy (EET) for dysplasia or early cancer. For confirmed low-grade dysplasia, high-grade dysplasia, or intramucosal (T1a) adenocarcinoma, EET is the standard of care and has largely replaced esophagectomy, avoiding its substantial morbidity and mortality (Shah et al., Nature Reviews Clinical Oncology, 2023; Shaheen et al., ACG Guideline, 2022). Any visible or raised lesion is first removed by endoscopic resection (EMR or ESD) for accurate staging, followed by ablation — most commonly radiofrequency ablation — of the remaining flat Barrett's segment, with the goal of complete eradication of dysplasia and intestinal metaplasia (Russin et al., Alimentary Pharmacology & Therapeutics, 2026; Sharma, JAMA, 2022). In randomized data, radiofrequency ablation eradicated dysplasia at 12 months in roughly 81–90% of patients and significantly reduced the risk of progression to cancer (Shah et al., Nature Reviews Clinical Oncology, 2023; Wani et al., AGA Expert Review, 2016). Because dysplastic Barrett's outcomes depend heavily on expertise, guidelines recommend referral to high-volume endoscopists and GI pathologists with access to multidisciplinary care (Rubenstein et al., AGA Guideline, 2024).
- Esophagectomy is now reserved for submucosal (T1b) or higher-stage cancer, bulky disease not amenable to endoscopic resection, or dysplasia refractory to EET (Trindade et al., Scientific Reports, 2022).
When to See a Doctor
Seek medical evaluation if you have long‑standing GERD, difficulty swallowing, unexplained weight loss, vomiting, anemia, or symptoms that worsen despite medication.
When to Seek Treatment
Treatment is recommended when GERD symptoms persist, when dysplasia is detected, or when Barrett’s progresses. Early intervention reduces cancer risk.
Long-Term Outlook
Barrett’s esophagus requires lifelong monitoring. Early detection and treatment of dysplasia significantly reduce the risk of esophageal cancer.
Prognosis
Most patients with non‑dysplastic Barrett’s have a low annual risk of cancer progression. With surveillance and treatment, outcomes are excellent.
Why Choose Dr. de la Cruz‑Muñoz
Dr. Nestor de la Cruz‑Muñoz provides comprehensive evaluation and management of Barrett’s esophagus, including advanced endoscopic therapy, surgical expertise, and long‑term surveillance programs to reduce cancer risk.
Featured Procedures
FAQ
It depends on whether dysplasia is present. For ordinary non-dysplastic Barrett's esophagus, acid-suppression alone does not reliably reverse it — long-term proton pump inhibitor (PPI) therapy may shrink the segment slightly and produce scattered islands of normal squamous lining, but complete regression is rare (Alkhayyat et al., Therapeutic Advances in Gastroenterology, 2020; Spechler et al., Yamada's Textbook of Gastroenterology, 2022). The goals of treatment for non-dysplastic disease are therefore reflux control and reducing the small risk of progression, not elimination of the Barrett's tissue itself, and endoscopic removal is not recommended at this stage (Fitzgerald, New England Journal of Medicine, 2026). When dysplasia or early cancer develops, Barrett's can effectively be eradicated with endoscopic eradication therapy — endoscopic resection of any visible lesion followed by radiofrequency ablation — which resolves intestinal metaplasia in up to ~77% and dysplasia in ~86% of cases and lowers the risk of progression (Rustgi & El-Serag, New England Journal of Medicine, 2014). Even after successful eradication, recurrence is possible, so ongoing surveillance remains necessary (Rustgi & El-Serag, New England Journal of Medicine, 2014). There is also evidence that antireflux surgery (fundoplication) achieves histologic regression more often than medical therapy, because it controls both acid and bile reflux (Wilson et al., Surgical Endoscopy, 2022).
Most people with Barrett's esophagus never develop esophageal cancer. For non-dysplastic Barrett's, the annual risk of progressing to esophageal adenocarcinoma is only about 0.2–0.5% per year (roughly 1 in 200 to 1 in 500 patients each year), and the risk is lower still for short segments under 3 cm (about 0.06% per year) than for longer segments (about 0.31% per year) (Sharma, JAMA, 2022; Spechler et al., Yamada's Textbook of Gastroenterology, 2022). The risk rises substantially only if dysplasia develops — roughly ~0.5–0.7% per year with low-grade dysplasia and 5–7% per year with high-grade dysplasia — which is precisely why surveillance endoscopy exists: to catch that change early when it is curable (Rustgi & El-Serag, New England Journal of Medicine, 2014; Fitzgerald, New England Journal of Medicine, 2026). Several steps may lower risk: daily PPI therapy is suggested to reduce neoplastic progression (AGA Guideline, Wani et al., 2025); smoking cessation and weight loss are recommended, since smoking, male sex, older age, and central obesity all increase progression risk (Sharma, JAMA, 2022; Wani et al., AGA Guideline, 2025); and statins have been associated with roughly a 47% lower odds of progression in observational data, though this is not yet guideline-endorsed as chemoprevention (Ko et al., Diseases of the Esophagus, 2025). Aspirin alone has not shown a clear independent benefit (AGA Guideline, Wani et al., 2025).
